En Es
Categories

Industry News

Una tecnología para la detección del cáncer basada en la IA recibe aprobación de la FDA

By Medimaging en español staff writers
02 Jan 2019

Imagen: ProFound AI es una solución de flujo de trabajo y detección de cáncer mediante aprendizaje profundo para la DBT (Fotografía cortesía de iCAD).Una solución nueva de software para la detección de cáncer que usa aprendizaje profundo para la tomosíntesis digital de seno (DBT, por sus siglas en inglés) ha recibido la aprobación de la FDA de los EUA para ventas comerciales y uso clínico en los EUA. La solución denominada ProFound AI se basa en inteligencia artificial (IA) y ha sido desarrollada por iCAD, Inc. (Nashua, NH, EUA), un proveedor de soluciones de terapia y detección para el cáncer.

ProFound AI es una solución de flujo de trabajo y detección de cáncer, de aprendizaje profundo para la DBT, que brinda beneficios críticos para los radiólogos, sus instalaciones y sus pacientes a través de una mejora en las tasas de detección del cáncer en un promedio del 8% y una reducción en las tasas innecesarias de llamar nuevamente a los pacientes en un promedio del 7%. La tecnología está entrenada para detectar densidades de tejidos blandos malignos y calcificaciones. También proporciona a los radiólogos información de puntuación que representa la probabilidad de que una detección o un caso sea maligno según el gran conjunto de datos de imágenes clínicas utilizadas para entrenar el algoritmo.

ProFound AI ha recibido la aprobación de la FDA en base a los resultados clínicos positivos de un gran estudio de lectores realizado a principios de este año y presentado en el congreso anual de la Sociedad Radiológica de América del Norte (RSNA) en Chicago, EUA. En el estudio, 24 radiólogos leyeron 260 casos de tomosíntesis, con y sin la solución ProFound AI. Los hallazgos del estudio revelaron mayores tasas de detección de cáncer, reducción de falsos positivos y necesidad de llamar nuevamente a los pacientes, y una disminución significativa de más del 50% en el promedio en los tiempos de interpretación.

“La obtención de la aprobación de la FDA para ProFound AI abre un mercado nuevo y sustancial direccionable para iCAD. Esto nos permite ofrecer a los médicos de todo el mundo una solución de flujo de trabajo y detección de cáncer sin rival basada en los últimos avances en aprendizaje profundo”, dijo Stacey Stevens, vicepresidenta ejecutiva y directora estratégica y comercial de iCAD. “Los resultados del estudio clínico de los lectores y las pruebas independientes completas han mostrado mejoras sin precedentes tanto en el desempeño clínico como en la eficiencia de la lectura. Estamos orgullosos de presentar una tecnología revolucionaria que transformará fundamentalmente la detección de cáncer de mama y la atención a los pacientes”.

Enlace relacionado:
iCAD, Inc.



E-mail Print
FaceBook Twitter Google+ Linked in

iCAD

Offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers
More info

More articles about iCAD

18 Sep 2019
AI Solution Supporting Wins Best New Radiology Solution Award
An FDA-cleared artificial intelligence (AI) solution that supports breast cancer detection in 3D tomosynthesis has been selected as the winner of “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program.
Read More
25 Dec 2018
Cancer Detection Technology Built on AI Receives FDA Clearance
A new deep-learning cancer detection software solution for digital breast tomosynthesis (DBT) has received clearance from the US FDA for commercial sales and clinical use in US. The solution named ProFound AI is built on artificial intelligence (AI) and has been developed by iCAD, Inc, a provider of cancer detection and therapy solutions.
Read More
25 Oct 2018
Study Demonstrates Advantages of AI for Digital Breast Tomosynthesis
A study of digital breast tomosynthesis (DBT) cancer detection software by iCAD, Inc. has demonstrated unprecedented improvements in clinical performance and reading times, validating the substantial benefits of Artificial Intelligence (AI) when used with three-dimensional (3D) mammography.
Read More

Additional news

25 Nov 2019
LANDAUER and RaySafe Exhibit New Products and Services at RSNA 2019
 LANDAUER (Glenwood, IL, USA) and RaySafe (Billdal, Sweden) showcased several new products and services at the Radiological Society of North America (RSNA) 2019 Annual Meeting held on December 1-5 at McCormick Place in Chicago, USA.
Read More
07 Nov 2019
Global Automated Breast Ultrasound Systems Market to Surpass USD 1.8 Billion by 2025
The global automated breast ultrasound systems (ABUS) market was valued at over USD 0.68 billion in 2018 and is projected to grow at a CAGR 16.1% during the forecast period, 2019-2025 to surpass USD 1.8 billion by 2025, driven by increasing government expenditure and rising awareness about breast cancer. Initiatives such as free check-up camps and symposiums for raising awareness regarding early detection and diagnosis of breast cancer will lead to greater adoption of ABUS in the coming years. However, stringent regulations and guidelines for the approval of ABUS, coupled with the high cost of diagnostic procedure, could hamper the market growth during the forecast period.
Read More
07 Nov 2019
CT System Receives FDA Clearance for AI-Based Image Reconstruction Technology
Canon Medical Systems USA, Inc. (Tustin, CA, USA; www.us.medical.canon) has received 510(k) clearance for its Advanced Intelligent Clear-IQ Engine (AiCE) for the Aquilion Precision, further expanding access to its new deep convolutional neural network (DCNN) image reconstruction technology. The technology, which is now available on Canon’s Aquilion Precision and Aquilion ONE/GENESIS Edition CT systems, uses a deep learning algorithm to differentiate signal from noise so that it can suppress noise while enhancing signal, thus improving CT image reconstruction.
Read More
07 Nov 2019
AI-Powered MRI Image Enhancement Software Receives FDA Clearance
A new image processing software that utilizes proprietary deep learning algorithms to bring the latest imaging enhancement technology to existing scanners has received 510(k) clearance from the US Food and Drug Administration (FDA). The software named SubtleMR uses denoising and resolution enhancement to improve image quality and has been developed by Subtle Medical (Menlo Park, CA, USA; www.subtlemedical.com), a healthcare technology company focused on improving the quality, efficiency, and accessibility of medical imaging.
Read More
06 Nov 2019
UCSF Launches Artificial Intelligence Center to Advance Medical Imaging
The University of California San Francisco {(UCSF) San Francisco, CA, USA; www.ucsf.edu} has announced the launch of a new center to accelerate the application of artificial intelligence (AI) technology to radiology, leveraging advanced computational techniques and industry collaborations to improve patient diagnoses and care. The Center for Intelligent Imaging, or ci2, will develop and apply AI to devise powerful new ways to look inside the body and to evaluate health and disease. The center aims to enable transformation via intelligent radiology, with the goal of again collaborating with the industry to become of the first institutions to bring medical imaging AI to the bedside.
Read More
06 Nov 2019
Global Blood Gas and Electrolyte Analyzers Market to Surpass USD 2.1 Billion by 2025
The global blood gas and electrolyte analyzers market is projected to grow at a CAGR of 6.5% during the forecast period, 2018-2025 to reach a value of over USD 2.1 billion by 2025, driven mainly by the Bench Top segment which is anticipated to bring in healthy gains and add significant momentum to the market growth. The Bench Top segment is projected to grow at a CAGR of over 6.4% during the forecast period.
Read More
06 Nov 2019
AI-Powered Diagnostics Software Guides Cardiologists during Angiography
Researchers are in the initial stages of a pivotal multi-center clinical trial to demonstrate the efficacy of AutocathFFR, a fully automated system that detects stenoses (narrowing) in the coronary arteries surrounding the heart. AutocathFFR provides cardiologists with the relevant physiological parameters that can help them in assessing the severity of their patients' condition and devise the optimal treatment strategy.
Read More
06 Nov 2019
IoT-Enabled Healthcare Equipment Market Projected to Reach USD 69.7 Billion by 2023
The global IoT-enabled healthcare equipment market is projected to grow at the rate of 29.9% annually from USD 18.8 billion in 2018 to USD 69.7 billion in 2023, driven by digitization during the forecast period. Medical devices companies are transforming from device or consumable providers to disease and care management organizations. Digitization in acute or chronic care is greatly aided by IoT-enabled medical devices, such as subcutaneous drug delivery units, continuous glucose monitors and vitals monitoring equipment. The emergence of digital enterprises such as Google and Apple in the consumer health space has led to development of new opportunities and innovations for medical devices companies.
Read More
05 Nov 2019
AI-Driven Software Uses CT Scans to Determine Extent of Brain Injury in Stroke Patients
A new study has shown that an artificial intelligence (AI) driven software can reliably tell doctors how much brain is injured in stroke patients using universally available CT scans, without the need for more complex advanced imaging.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions